All News

T%20cell.jpg

Holes in TH17 cells release IL-1α on NLRP3 activation

d EurekAlert!

Certain T cells can secrete cytokines that are normally part of the innate immune system, as researchers from the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) and an international research team discovered.

Read Article
PMR spotlight

JAK Inhibitor Promising for Polymyalgia Rheumatica

d MedPage Today

Tofacitinib (Xeljanz) appeared highly effective against polymyalgia rheumatica (PMR) in a small single-arm trial, researchers said, suggesting another potential alternative to long-term corticosteroids.

Read Article
Vertbral,Fracture,spine,compression

ACP Guidelines on Fracture Prevention in at-risk Adults

d Jack Cush, MD

The American College of Physicians (ACP) has updated its 2017 recommendations on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults. The full document and guideline can be found in the Annals of Internal Medicine.

Read Article
smoke.cannabis.hookah.weed_.jpg

Cannabis Use for Pain is Common

d Jack Cush, MD

In states with legalized medical cannabis use, 3 in 10 persons are using cannabis to manage their pain.

Read Article
2022 Memorium Sadly, too many of our rheumatology colleagues passed on in 2022. Here is an (incomplete) list of notable brethren, mentors, do-gooders and great rheumatologists. https://t.co/wtr4ablgUm https://t.co/xPpgnrEQWz

Links:

Dr. John Cush RheumNow ( View Tweet)
2022 Rheumatology Year in Review Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown. https://t.co/6r6W95moyr https://t.co/PNlMDId7qX

Links:

Dr. John Cush RheumNow ( View Tweet)
AutoAb analysis of 140 systemic sclerosis shows low sensitivity (<33%), high specificity (>88%). Scl-70+ signif assoc w sine scleroderma, digital ulcers, Raynauds as 1st onset sign. SSc-ILD more common Scl-70 and PAH with CENP A/B Abs https://t.co/1zvkte4drJ https://t.co/FaSmshUvhY

Links:

Dr. John Cush RheumNow ( View Tweet)
PsABiostudy followed PsA pts starting TNFi vs ustekinumab x12 mos showing equivalent durability at 1 yr (72% vs 71%). cDAPSA LDA was seen in 56% UST vs 67% TNFi (similar for MDA (34% vs 43%) https://t.co/briK7itZtL https://t.co/Rq1SXA7s1s

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Database 1,955 breakthrough COVID-19 infxs in 54,576 #gout pts compared to 52,468 w/o gout saw more in gout (adj HR 1.24), also w/ more #COVID hospitalizations (adj HR 1.30) & death (1.36), more so in women. Same for unvaccinated https://t.co/596KvupZxi https://t.co/BJJguQBdin

Links:

Dr. John Cush RheumNow ( View Tweet)
Autoimmune Dz may be assoc w/ new-onset Atrial Fibrillation, esp in women. Population-based UK Biobank found significant increases for AFib in Rheumatic fever w/o CVD (HR 1.47), Crohn’ (1.23), UC(1.17), RA (1.39), PAN (1.82), SLE (1.82), PSS (2.32) https://t.co/rpIiztUfg9 https://t.co/FWmLiZ6x1S

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie has forcasted sales sales revenues in 2025 for Skyrizi and Rinvoq to be more than $17.5 billion. This year Humira goes off patent. https://t.co/YrIdkEhL7M https://t.co/MuuVYkyXRv

Links:

Dr. John Cush RheumNow ( View Tweet)
Status of #RA; an Egyptian College of Rheumatology study of 10,364 pts from 26 centers. Mean age 45 yrs, Dz duration 6.4 yrs, onset age 38. (F:M 5.4:1) DAS28 was 4.4  & HAQ 0.95  RF+ 74%, CCP+ 67% Rx use: MTX 78%, HCQ 74%, steroids 71%, Biologics 11.6% https://t.co/19omwKqAQl https://t.co/m04QabOwgZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update https://t.co/2lwWc8PqIw https://t.co/uYdYwJofwJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Network meta-analysis of 152 RCTs (17431 pts) comparing efficacy of exercise therapy, NSAIDs, Tylenol for knee or hip osteoarthritis: Found all 3 equivalent at 4 wk, 8 wk and 24 wks. https://t.co/rKck2AacL4 https://t.co/YEAMh9UxTs

Links:

Dr. John Cush RheumNow ( View Tweet)
Remibrutinib in Sjogren's Syndrome Dr. Michael Putman reports on abstract 1113 presented at ACR22. Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study https://t.co/4UAxMq2z0X https://t.co/kzinfgDGZr

Links:

Dr. John Cush RheumNow ( View Tweet)
PHYSICIANS: Current, routine, outpatient clinic visits - do you require masks

Dr. John Cush RheumNow ( View Tweet)

FDA Accepts Biologics License Application for CT-P13 SC, a Subcutaneous Formulation of Infliximab (Celltrion) that is approved in other countries. https://t.co/G1OIoqk9ga https://t.co/NEWFNlKhlU

Links:

Dr. John Cush RheumNow ( View Tweet)
Neutrophil-to-lymphocyte ratio (NLR) was studied in 205 Idiopathic pulmonary fibrosis (IPF) pts - NLR correlated with lung function, & outcomes - NLR >= 2.9 was associated with a significant 2 fold increased risk of mortality https://t.co/FCuKx2NfeC https://t.co/iIb9uIGBAE

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatology Giants in who passed away in 2022: Eric Gall William Wilke John Winfield Peter Simkin Roy Altman Samuel Strober James Fries Robert Lightfoot Bart Lindsley https://t.co/BX3fGBVre7 https://t.co/ToxZOZHOhU

Links:

Dr. John Cush RheumNow ( View Tweet)
For 2023 - what you going to focus on with your patients? Same ole, same ole means youre not getting better. How about focusing on 2 main messages, mine would be patient "STRENGTH" and "COMPLIANCE" (meaning more Rx education) https://t.co/fEIVYk6Z9m
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×